drugset / Trial / NCT01334957

Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

NCT01334957

Phase 4 Completed 300 enrolled Cumberland Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the safety of a single dose of intravenous ibuprofen administered over 5-10 minutes for the preemptive treatment of postoperative pain.

Timeline

Start
2011-06
Primary completion
2012-12
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 800 mg Intravenous

Indications

No indication recorded.